• Lymphoma & blood cancers
Name No. Patient Profile Purpose
CALLS (INCB 84344-401) 18-48

Participants with Chronic Myeloid Leukaemia (CML) and Philadelphia-positive Acute Lymphoid Leukaemia (Ph+ALL) who are being treated with their first or subsequent tyrosine kinase inhibitor (TKI) therapy.

The purpose of this observational study is to evaluate the prevalence of mutations in patients with Chronic Myeloid Leukaemia (CML) who meet the European Leukaemia Net (ELN) criteria for warning or failure and patients with Philadelphia-positive Acute Lymphoid Leukaemia (Ph+ALL) with detectable BCR-ABL currently being treated with first or subsequent Tyrosine Kinase Inhibitor (TKI) therapy in the UK, Ireland, or France using Next-Generation Sequencing.
  • Lymphoma & blood cancers
  • Lymphoma
Name No. Patient Profile Purpose
Paradigme (LYMRIT-37-01) 18-15

Follicular Lymphoma that did not respond to treatment or recurred after chemotherapy or immunotherapy treatment.

To investigate the efficacy and safety of a new drug called Betalutin®. One dose of Betalutin® is given to patients. Betalutin® is an antibody which targets a protein on lymphoma cancer cells together with radioactivity to kill the cancer cells. Two doses of Betalutin® are used in this clinical trial and all patients receive Betalutin®. Patients will be requested to return to clinic for up to 5 years to have their cancer assessed and to collect any side effects.
  • Lymphoma & blood cancers
  • Lymphoma
Name No. Patient Profile Purpose
CheckMate 744 17-07

Children, adolescents, and young adults with Classic Hodgkin Lymphoma whose disease has come back or did not respond to initial treatment.

The purpose of this study is to determine whether certain drug combinations are safe and effective.
  • Lymphoma & blood cancers
  • Lymphoma
Name No. Patient Profile Purpose
CHRONOS-4 17-06

Indolent (grow slowly) Non-Hodgkin’s Lymphoma that have returned after previous treatment.

The purpose of this study is to evaluate the efficacy and safety of copanlisib in combination with standard immunochemotherapy.
  • Lymphoma & blood cancers
  • Lymphoma
Name No. Patient Profile Purpose
CHRONOS-3 15-38

Indolent B-cell non-Hodgkin’s lymphoma that has returned.

The purpose of this trial is to find out if the drug copanlisib in combination with rituximab is superior to placebo in combination with rituximab.
  • Lymphoma & blood cancers
  • Acute Leukaemia
Name No. Patient Profile Purpose
Protocol 04-30 15-36

Myelodysplastic Syndrome after failure of drugs called Hypomethylating Agents

The purpose of this trial is to evaluate whether adding the drug rigosertib to the patient’s doctor’s choice (standard of care treatment) works better and is as safe as the doctor’s choice.